| Market revenue in 2025 | USD 3,911.5 million |
| Market revenue in 2033 | USD 6,321.3 million |
| Growth rate | 6.3% (CAGR from 2026 to 2033) |
| Largest segment | Active pharmaceutical ingredients (api) |
| Fastest growing segment | Active Pharmaceutical Ingredients (API) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Active Pharmaceutical Ingredients (API), Finished Drug Products |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Eurofins Scientific SE, Aurigene Pharmaceutical Services |
Publish Date: Aug 13, 2025
Last Updated: Aug 26, 2026
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Aurigene Pharmaceutical Services | View profile | 501-1000 | Bangalore, Karnataka, India, Asia | www.aurigeneservices.com |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Small Molecule CDMO Market Outlook will help companies and investors design strategic landscapes.
Active Pharmaceutical Ingredients (Api) was the largest segment with a revenue share of 65.44% in 2025.
Horizon Databook has segmented the U.K. small molecule cdmo market based on active pharmaceutical ingredients (api), finished drug products covering the revenue growth of each sub-segment from 2021 to 2033.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. small molecule cdmo market report, including forecasts for subscribers. This country databook contains high-level insights into U.K. small molecule cdmo market report from 2021 to 2033, including revenue numbers, major trends, and company profiles.